Enliven therapeutics reports third quarter financial results and provides a business update

Announced positive data from the phase 1 clinical trial of elvn-001 in cml, reporting a cumulative mmr rate of 44% (8/18) by 24 weeks and showing that elvn-001 remains well-tolerated with no dose reductions continued to progress elvn-002 with a focus on recently initiated combination clinical trials evaluating patients with her2+ mbc and crc strong balance sheet with $292 million in cash, cash equivalents and marketable securities, which is expected to provide cash runway into late 2026 boulder, colo. , nov. 13, 2024 /prnewswire/ -- enliven therapeutics, inc. (enliven or the company) (nasdaq: elvn), a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics, today reported financial results for the third quarter ended september 30, 2024, and provided a business update, including highlights of pipeline progress.
ELVN Ratings Summary
ELVN Quant Ranking